1. Home
  2. NCPL vs LYRA Comparison

NCPL vs LYRA Comparison

Compare NCPL & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCPL

Netcapital Inc.

HOLD

Current Price

$0.69

Market Cap

5.9M

Sector

Finance

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.98

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCPL
LYRA
Founded
1984
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NCPL
LYRA
Price
$0.69
$1.98
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
1.7M
102.7K
Earning Date
12-15-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$797,839.00
$600,000.00
Revenue This Year
$739.37
N/A
Revenue Next Year
N/A
$93.90
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$1.63
52 Week High
$8.75
$37.50

Technical Indicators

Market Signals
Indicator
NCPL
LYRA
Relative Strength Index (RSI) 38.52 27.52
Support Level $0.72 $1.63
Resistance Level $0.89 $3.94
Average True Range (ATR) 0.07 0.25
MACD 0.02 -0.14
Stochastic Oscillator 27.78 15.37

Price Performance

Historical Comparison
NCPL
LYRA

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: